Use of the BRANT-MERQS scoring table for the quality assessment of type 3 medication review in patients with rheumatoid arthritis and those with type 2 diabetes mellitus
This study demonstrated the feasibility of MR3 quality assessment through a scoring system. However, it also unveiled the tool's current imperfections and highlighted the ongoing need for refinement, something expected of a new service in an implementation phase.
Authors
- Stéphane Steurbaut (ORCID: https://orcid.org/0000-0003-4586-6919)
- Laura Poppe
- Guido R.Y. De Meyer (ORCID: https://orcid.org/0000-0003-3848-8702)
- Hans De Loof (ORCID: https://orcid.org/0000-0003-4488-551X)
- Anneleen Robberechts (ORCID: https://orcid.org/0000-0003-3342-3870)
- Margot Puttemans
- Kaat Stas
Institutions
- Vrije Universiteit Brussel (BE)
- University of Antwerp (BE)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-08-16
- DOI
- https://doi.org/10.3389/fphar.2024.1359568
- Citations
- 2
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.69